[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100486845":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":14,"locations":7,"responsibleParty":20,"collaborators":7,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":7,"acronym":7,"eligibilityCriteria":7,"healthyVolunteers":24,"sex":27,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":28,"phases":7,"briefSummary":29,"conditions":30,"keywords":7,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":40,"locationsCount":7},{"fullName":5,"class":6},"Regeneron Pharmaceuticals","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":12},"DRUG","Odronextamab",[13],"REGN1979",[15],{"name":16,"role":17,"phone":18,"phoneExt":7,"email":19},"Requests for compassionate use must be initiated by a treating physician Physicians should contact","CONTACT","844-734-6643","CompassionateUseRequests@regeneron.com",{"type":21,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100486845","a-compassionate-use-cu-program-of-odronextamab-100486845",false,"NCT05619367","A Compassionate Use (CU) Program of Odronextamab","ALL","EXPANDED_ACCESS","Provide compassionate use of odronextamab",[31,32,33,34],"Relapsed or Refractory (R\u002FR) Follicular Lymphoma (FL)","Diffuse Large B-Cell Lymphoma (DLBCL)","B-Cell Non-Hodgkin Lymphoma (NHL)","High-Grade B-Cell Lymphoma (HGBCL)","AVAILABLE","2025-12-22",{"date":38,"type":39},"2025-12-23","ACTUAL",{"name":5,"class":6}]